Beta Drugs Q1FY27 Revenue Up 25% to ₹1,255 Crore, PAT Rises 41%
Beta Drugs reported Q1-FY27 revenue of ₹1,255 Crore, up 25.2% YoY. PAT increased by 41% to ₹165 Crore. Branded Oncology grew 47%, CMO by 41%, and Exports by 25.2%. The company reiterated its FY27 revenue growth guidance of 20-25%.
The significant year-on-year growth in revenue and profit, coupled with strong performance across multiple business verticals and a clear forward-looking guidance, indicates a substantial positive impact on the company's financial health and market position.
The company reported strong year-on-year growth in revenue, PAT, and EBITDA, driven by robust performance in key business segments like Branded Oncology and CMO. The improved gross margins and reiterated growth guidance further contribute to a positive sentiment.
Beta Drugs Limited (BETA) announced its financial results for the first quarter of FY27, reporting a consolidated revenue of ₹1,255 Crore, a significant increase of 25.2% year-on-year from ₹1,002 Crore in Q1-FY26. The company's Profit After Tax (PAT) also saw a substantial jump of 41% to ₹165 Crore, compared to ₹117 Crore in the same period last year. EBITDA grew by 39.1% to ₹274 Crore.
The Branded Oncology business demonstrated stellar performance, with a growth of 47% year-on-year, achieving sales of ₹330 Crore, driven by existing products and new launches. The Contract Manufacturing (CMO) business also performed robustly, growing by 41% year-on-year to ₹474 Crore, attributed to strong customer traction and new proprietary NDDS product launches. Exports generated ₹172 Crore in revenue, with expectations of stronger momentum as order inflows accelerate.
The recently acquired Nivian business (IVF) delivered 45% YoY growth, contributing to the overall performance. The company's gross margin improved to 56.6% from 50.4% in Q1-FY26, reflecting a favourable shift towards higher-margin branded and export businesses. BETA continues to invest in innovation, with a pipeline of NDDS and First-to-Launch products planned for FY27 and FY28. The company reiterated its Vision 2030 targets, maintaining a consolidated revenue growth guidance of 20-25% for FY27 and a long-term goal of deriving over 50% of revenue from its own branded products.
What to do with a filing like this
Beta Drugs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Beta Drugs Limited. Read the original for the full detail.